ISID Knowledge Exchange & E-Learning Platform (IKEEP)

ISID Knowledge Exchange &

E-Learning Platform (IKEEP)

ISID Knowledge Exchange & E-Learning Platform (IKEEP)

The ISID Knowledge Exchange & E-Learning (IKEEP) is an online resource that shares open-access educational modules, webinars, and interactive discussions. ISID’s new online learning environment focuses on sharing evidence-based information for infectious disease management, control and prevention in resource-limited settings.

The content hosted on IKEEP serves as an enduring resource for practitioners around the globe with a focus on low- and middle-income countries. Launched in October 2020, IKEEP regularly shares critical infectious disease knowledge covering a range of global infectious disease priorities and provides content focused on career development and leadership skill-building.

Visit IKEEP

Join the IKEEP Mailing List

Coming Soon to IKEEP

Date of Event: September 15, 2021

Speakers:

Dr. Anthony Fiore, MPH, USA

Prof. Paul Tambyah, Singapore

Moderators:

Prof. Marc Mendelson, ISID Past President, South Africa

Dr. Afreenish Amir, ISID Emerging Leader, Pakistan

Abstract: Antimicrobial resistance (AMR) is one of the biggest global health threats. Antibiotics are becoming increasingly ineffective as drug-resistance spreads leading to more difficult to treat infections. Fighting this threat is a public health priority that requires a collaborative global approach across sectors. Controlling AMR demands improvements in infection prevention, antimicrobial stewardship, and antimicrobial discovery. A powerful measure to reduce the use of antimicrobials, and hence development of resistance, is to prevent the occurrence of infections. Vaccines can impact AMR in two ways. Vaccines can reduce or eliminate the risk of infection due to antibiotic-resistant strains, for example pneumococcal vaccine. Vaccines can also have a secondary effect on AMR by preventing antibiotic use by reducing the rates of viral febrile illness episodes and the likelihood of secondary bacterial infections following the prevented episode. Viral infections are a strong driver of use and misuse of antibiotics and vaccines are an impactful and effective public health measure for the prevention of many viral infections. Single or combination vaccines may ultimately result in synergistic effects on decreasing antimicrobial use and therefore resistance. In this way, vaccines targeting viral illnesses become a tool to reinforce policies of antibiotic stewardship. WHO has developed a strategy to articulate the role of vaccines against AMR and an action framework that describes a vision for vaccines to contribute fully, sustainably and equitably to the prevention and control of antimicrobial resistance by preventing infections and reducing antimicrobial use. During this webinar, speakers will discuss how vaccines targeting viral illnesses contribute to the battle against AMR by preventing infections and by reducing antimicrobial use.

 

Available now on IKEEP

Speakers:

•  Prof. Eskild Petersen, Denmark: Editor in Chief

•  Prof. Shui Shan Lee, Hong Kong, Associate Editor

Facilitated by Theresa L. Schraeder, M.D.

Produced by Amador (Tino) Delamerced, B.A.

Description:

The learning objectives of this podcast are:

  1. Learn more about the International Journal of Infectious Diseases (IJID)
  1. Review important instructions for authors
  1. Highlight specific lessons for research and writing
  1. Discuss common mistakes in submitting a manuscript

* This podcast is supported by an Unrestricted Educational Grant from Pfizer. 

Listen Here

Presentando:

Prof. Alfonso Rodriguez-Morales, Technological University of Pereira, Colombia

Unusual Presentations

Prof. Bridget Wills, Oxford University Clinical Research Unit, Vietnam

Clinical Management - Innovations and Controversies

Moderado por:

Prof. Neelika Malavige, ISID Executive Committee, Sri Lanka

Dr. Laura Talarico, ISID Emerging Leader, Argentina

Descripción:

El dengue es una de las enfermedades virales transmitidas por mosquitos más comunes en todo el mundo. El dengue causa un amplio espectro de enfermedades que van desde enfermedades subclínicas hasta síntomas graves similares a los de la gripe en las personas infectadas. En la actualidad, el dengue grave afecta a la mayoría de los países de Asia y América Latina y se ha convertido en una de las principales causas de hospitalización y muerte entre niños y adultos en estas regiones. Los síntomas y los hallazgos de laboratorio similares entre el dengue y la enfermedad por coronavirus (COVID-19) pueden representar un desafío para el diagnóstico en los países donde el dengue es endémico. Los oradores discutirán el uso de diagnósticos con un enfoque en la implementación en regiones endémicas y presentarán innovaciones y controversias en el manejo clínico del dengue severo, incluido el uso de terapias novedosas. Los oradores también destacarán los desafíos de las presentaciones inusuales que ahora se ven con mayor frecuencia, incluido el daño orgánico específico inducido por el dengue no relacionado con el shock, como la enfermedad hepática o la encefalitis, y las presentaciones en los ancianos.

* Este seminario web está financiado por una beca educativa sin restricciones de Takeda.

Ver Ahora

Speaker: 

Teresa L. Schraeder, M.D.

Abstract:

This workshop will help you learn more about the news media including their roles, responsibilities, training, needs, deadlines and motives. We will discuss the impact of the media on perceptions, understanding and behavior of the public, patients, societies, institutions, and governments. You will learn lessons and specific skills to help you prepare to engage with the media. You will learn how to educate and inform the public on different topics in different settings and regarding types of events through the media. We will review the potential benefits and risks of engaging with the media.

*This workshop is supported by the Bill & Melinda Gates Foundation.

Watch Here

Speakers:

Prof. Alfonso Rodriguez-Morales, Technological University of Pereira, Colombia

Unusual Presentations

Prof. Bridget Wills, Oxford University Clinical Research Unit, Vietnam

Clinical Management - Innovations and Controversies

Moderators:

Prof. Neelika Malavige, ISID Executive Committee, Sri Lanka

Dr. Laura Talarico, ISID Emerging Leader, Argentina

Abstract: 

Dengue is one of the most common mosquito-borne viral illnesses worldwide. Dengue causes a wide spectrum of diseases ranging from subclinical disease to severe flu-like symptoms in those infected. Today, severe dengue affects most Asian and Latin American countries and has become a leading cause of hospitalization and death among children and adults in these regions. Similar symptoms and laboratory findings between dengue and coronavirus disease (COVID-19) can pose a diagnostic challenge in dengue-endemic countries. Speakers will discuss the use of diagnostics with a focus on implementation in endemic regions and present innovations and controversies in the clinical management of severe dengue, including the use of novel therapeutics. Speakers will also highlight the challenges of unusual presentations that are now seen in higher frequency including Dengue-induced organ-specific damage unrelated to shock such as liver disease or encephalitis and presentations in the elderly.

*This webinar is supported by an Unrestricted Educational Grant from Takeda.

Watch Here

Speakers:

Dr. Mirfin Mpundu, Director, ReAct Africa, Zambia

Successful Implementation of Antimicrobial Stewardship Programs in Resource-Constrained Settings

Dr. Manica Balasegaram, Queen Elizabeth Central Hospital, Switzerland

Introducing New Antimicrobials for Multi-drug Resistant Pathogens in High Endemic Settings

Moderators:

Prof. Alison Holmes, President, ISID, UK

Dr. Esmita Charani, ISID Emerging Leader, UK

Abstract: 

Antimicrobial resistance is one of the biggest threats to global health accelerated, in part, by the misuse of antibiotics. The lack of access to antibiotics in resource constrained settings continues to cause significant morbidity and mortality, while the overuse of antibiotics accelerates the global spread of drug resistant organisms. It is critical to ensure access to appropriate antimicrobials while measuring and improving prescribing practices of clinicians and use by patients. During this webinar, speakers will address the unique challenges of successfully implementing antimicrobial stewardship programs in resource constrained settings to optimize clinical outcomes while minimizing unintended consequences of antimicrobial use such as: toxicity, selection of pathogenic organisms (Clostridioides difficile), and the emergence of resistance. They will discuss the introduction of new antimicrobials in high-endemic settings and ways to ensure these treatments are available to those in need while also using them sparingly to limit the development of drug resistance.

*This webinar is supported with an Unrestricted Educational Grant from bioMérieux.

Watch Here

Speakers:

Prof. Thuy Le, Duke University, United States

Talaromyces marneffei

Prof. Henry Mwandumba, Queen Elizabeth Central Hospital, Malawi

Cryptococcus neoformans

Moderators:

Professor William Hope, University of Liverpool, UK

Professor Sophie Yacoub, ISID Emerging Leader, Vietnam

Abstract: 

The aim of implementing an antifungal stewardship program is to optimize the use of antifungal drugs to achieve the best outcomes while minimizing adverse events and the emergence of resistance. Antifungal stewardship is less established than antibacterial stewardship because of a narrower and more complex evidence base along with fewer available drugs. Moreover, the diagnosis of fungal infections can be complex with an urgent need for reliable noninvasive and rapid diagnostic tests that can be used across different resource levels. During this session, experts will provide updates on the diagnosis, treatment, monitoring and prevention strategies for Cryptococcus neoformans and Talaromyces marneffei (formerly Penicillium marneffei), both important opportunistic pathogens in patients with AIDS and other immunosuppressive conditions. Focus will be on diagnostic options and treatment and prevention strategies in areas with highest burden of disease, from Southeast Asia to southern China and sub-Saharan Africa.

*This webinar is supported with an Unrestricted Educational Grant from bioMérieux.

Watch Here

Introduction:

Dame Sally Davies, UK Special Envoy, AMR

Speakers:

Dr. Ghassan Matar, Lebanon

Dr. Sophie Bowman-Derrick, Australia

Mr. Emmanuel Benyeogor, Nigeria

Moderator:

Dr. Matt Levison, Chair, US

Abstract: 

Antimicrobial resistance (AMR) is one of the greatest challenges in modern medicine. Often referred to as the ‘slow-burning pandemic’, AMR is estimated to cause 700,000 deaths annually. This statistic does not consider deaths among animals and the impact AMR has on our food system and the environment. To preserve the effectiveness of these therapies, we must change our use behaviors to limit the unnecessary use of these treatments. This webinar highlights the universal challenge of AMR and shines a light on critical issues that must be addressed quickly. Attendees will hear from experts in the AMR field, and user-submitted questions will be answered by AMR experts who operate the ProMED-AMR infectious disease surveillance network. Specific topics addressed throughout the presentation include the global impact of AMR, AMR and the One Health Paradigm, AMR in the veterinary community, AMR surveillance, and AMR in the era of ‘big data.

*This event is made possible with the support of Public Health England (PHE). 

Watch Here

Speakers:

Prof. Ann Falsey, Professor of Medicine, University of Rochester School of Medicine, New York, USA

The Global Burden of Influenza Morbidity and Mortality

Prof. Bruno Lina, Professor of Virology, Lyon, France

The Impact of COVID-19 on Influenza Surveillance and Transmission 

Prof. Zamberi Sekawi, ISID Executive Committee Member, Malaysia

The Impact of Influenza Vaccines on Public Health

Moderators:

Prof. Patricio Acosta, Hospital de Niños Ricardo Gutiérrez - CONICET, Argentina

Dr. Therese Umuhoza, ProMED Moderator, Rwanda

Abstract: 

WHO estimates that seasonal influenza may result in 290,000 – 650,000 deaths each year due to respiratory diseases alone. This estimate does not take into account deaths from other diseases such as cardiovascular disease, which can be influenza-related. Surveillance and laboratory studies of all influenza-related diseases are ongoing and are expected to reveal substantially higher estimates of disease burden. Webinar attendees will engage with experts who will provide updates on global influenza surveillance efforts and estimated burden of disease. They will discuss the importance of country-level influenza estimates to inform national and global preparedness, prevention and control efforts and will highlight remaining gaps. The clinical, social, and economic advances gained from expanded access and uptake of influenza vaccines will be addressed and the lack of reliable data on the possible impact of vaccination among specific high-risk groups will be highlighted.  

The full impact of COVID-19 and non-pharmaceutical interventions on seasonal influenza remains to be determined. Experts will discuss questions around the impact of COVID-19 on influenza surveillance, the role of genomic sequencing for influenza surveillance as a way to better understand disease spread and improve prevention efforts and what to expect during the next influenza season.

*This webinar is supported by an Unrestricted Educational Grant from Sanofi Pasteur.

Watch Here

Speakers:

Dr. Brenda Kwambana-Adams, Research Associate, Division of Infection & Immunity, University College, London, United Kingdom

Equitable and Sustainable Access to Meningococcal Vaccines

Prof. Marco A. Safadi, Head, Department of Pediatrics, Santa Casa de São Paulo, Brazil

Atypical Presentations and the Impact of COVID-19

Moderators:

Prof. Rob Heyderman, ISID Executive Committee Member, UK

Dr. Christina Obiero, ISID Emerging Leader, Kenya

Abstract:

Meningococcal meningitis is a devastating disease with high mortality and long-term sequelae even in successfully managed cases. Although the burden of disease is greatest in the meningitis belt of sub-Saharan Africa, meningitis is a world-wide threat. Recent epidemics in Liberia, Nigeria, Togo, Niger, Guinea, Kyrgyzstan, Fiji and Chile and the spread of some virulent strains across the world has emphasized the need for a global approach to surveillance and prevention.

In this session, experts will discuss the urgent need for improved monitoring of invasive meningococcal disease and sequelae globally, will discuss the use of whole genome sequencing, strain typing and rapid diagnostics to better understand outbreak epidemiology and burden of disease and will provide updates on the emergence of new clones and hypervirulent strains. They will review WHO’s recently released Defeating Meningitis by 2030 Global Roadmap and what it will take to make vaccines widely available in low- and middle-income countries.

The clinical presentations of meningococcal disease can vary. Recent observations suggest that certain serogroups may present with atypical signs and symptoms such as acute gastrointestinal symptoms, septic arthritis, bacteremic pneumonia or severe upper respiratory infection. Experts will discuss atypical clinical presentations which can be associated with higher case fatality rates and misdiagnoses. The immediate and longer-term impact of COVID-19 on meningococcal disease and meningococcal vaccine schedules is currently unclear and needs to be determined.

*This webinar is supported by an Unrestricted Educational Grant from Sanofi Pasteur.

Watch Here

Speakers: Assistant Prof. Michelle Doll, Prof. Shaheen Mehtar, Prof. Ziad Memish, Prof. Victor Rosenthal, Prof. Mike Stevens, Prof. Sade Ogunsola

Moderator: Prof. Gonzalo Bearman

Abstract: The ongoing COVID-19 pandemic has highlighted both challenges and opportunities for infection control practices at healthcare facilities around the globe. In this moderated discussion, infection prevention and control experts will describe how they responded to the pandemic and what they did to quickly adapt existing helathcare protocols. Speakers will describe how these approaches and the lessons learned from the COVID-19 pandemic can help us better prepare for future outbreaks. Questions addressed during this webinar will include: Will the re-use of presonal protective equipment become standard practice in the future? What can we experct in terms of face mask requirements over the next few years? How can surveillance, reporting and laboratory structures established during the pandemic be maintained in the future?

Watch Here

Speaker: Dr. Terry Schraeder

Abstract: Physicians and healthcare leaders may have many important opportunities to give public speeches and presentations as well as engage with traditional and digital media throughout their careers. Speaking to live audiences, giving online video presentations, answering questions at press conferences and being interviewed by journalists are just a few examples. Learning how to be confident, clear, calm, concise, and engaging in front of an audience, as well as honing the message and improving specific communication skills in a variety of settings are imperative to help optimize a speaker’s message and mission. 

Watch Here

Speaker: Prof. Shabir Madhi, University of Witwatersrand, South Africa

Moderator: Prof. Neelika Malavige, ISID Executive Committee Member, Sri Lanka

Abstract: The emergence and spread of COVID-19 variants raises new questions and scientists must debate whether the variants undercut the effectiveness of first-generation COVID-19 vaccines. The new strains of SARS-CoV-2, first identified in the United Kingdom (B.1.1.7), Brazil (P.1) and South Africa (B.1.351), have developed a substantial number of mutations, especially in the S-protein, that seem to reduce the effects of antibodies crucial to fending off infection. This webinar is a follow up to ISID’s webinar on “COVID-19 Vaccinology Update: Development, Use and Effect on Public Health” released in January 2021. Prof. Malavige and Prof. Madhi will discuss the implications of these mutations on vaccine response and how vaccine manufacturers plan to update their vaccines to better target the emerging variants. Additionally, Prof. Madhi will discuss new results from phase 3 trials and what it will take to achieve herd immunity.

Watch Here

Speaker: Prof. Lisa Ng, Singapore Immunology Network A*STAR, Singapore

Moderator: Prof. Robert Heyderman, ISID Executive Committee Member, United Kingdom

The exact duration of immunity induced by natural COVID-19 infection of the newly produced COVID-19 vaccines is still unclear. Natural infection and coronavirus vaccines induce both humoral (antibody-induced) and cellular immune responses and both are important for protection from COVID-19. Multiple studies indicate that neutralizing antibodies decline 6 months after natural infection and it is not yet clear if cellular immunity will provide longer protection. Some studies show the more severe the natural COVID-19 infection, the higher the immune response and the longer the protection. During this session, experts will discuss the implications fo emerging variants for natural re-infection, vaccine escape and antibody treatments. They will explain the concept of herd immunity as a key concept of epidemic control and discuss the current understanding of protective COVID-19 immune responses in special populations such as the elderly, children and the obese. There will be time for questions from the audience.

Watch Here

*This webinar is supported by an Unrestricted Educational Grant from Pfizer Global Medical Grants.

*Please Note: Due to the rapidly evolving COVID-19 environment, some of the information presented in this webinar may no longer be up to date.

Presentado: Dr. Majorie Pollack, USA & Dr. Uzma Bashir Aamir, Pakistan

Moderado por: Dr. Therese Umuhoza, Kenya

Abstract: En la noche del 30 de diciembre de 2019, la Editora Adjunta del Programa de Monitoreo de Enfermedades Emergentes (ProMED) de ISID, la Dra. Marjorie Pollack publicó una solicitud de información a la red ProMED después de ser contactada por un colega de confianza sobre un grupo de casos de neumonía no diagnosticados en Wuhan, China. A través de su experiencia previa con SARS décadas antes, Marjorie sabía que esta nueva amenaza debía tomarse en serio. Afortunadamente sonó la alarma, y al hacerlo fue la primera en proporcionar un informe detallado alertando a la comunidad internacional de enfermedades infecciosas sobre lo que evolucionó en lo que ahora conocemos como la pandemia global de COVID-19. Con su colega, la Dra. Uzma Aamir, este seminario web es una discusión cercana y personal con Marjorie, moderada por la Dra. Therese Umuhoza.

Ver ahora

Speakers:

Prof. Gagandeep Kang, ISID Executive Committee Member, India

  • Global Access

Dr. Heidi Larson, The Vaccine Confidence Project, United Kingdom

  • How Vaccine Rumors Start & Why They Don’t Go Away

Moderator: Prof. Paul Tambyah, ISID President-Elect, Singapore

Abstract: The development of accepted vaccines that are available on a global scale is a priority to end the COVID-19 pandemic. Recently, there have been dramatic shifts in vaccine confidence around the world that threaten the success of approved COVID-19 vaccines as well as the likelihood of achieving herd immunity. This webinar will discuss the current state of COVID-19 vaccine confidence, reasons for hesitancy, and will propose ways forward. The need for COVID-19 vaccines is global, although the need is differentially distributed within populations. High income countries must not monopolize the global supply and every effort must be made to provide vaccines at a price affordable to low- and middle-income countries. Understanding the complexities of establishing a regionally and globally fair vaccine-allocation system are essential.

Watch Here

*This webinar is supported by an Unrestricted Educational Grant from Pfizer Global Medical Grants.

*Please Note: Due to the rapidly evolving COVID-19 environment, some of the information presented in this webinar may no longer be up to date.

Speaker: Prof. Angela Gentile, University of Buenos Aires, Argentina

Moderators: Prof. Miguel O'Ryan, ISID Executive Committee Member, Chile & Dr. Tatiana Pinto, ISID Emerging Leader, Brazil

Abstract: El desarrollo de vacunas aceptadas que estén disponibles a escala global es una prioridad para finalizar la pandemia de COVID-19. Recientemente, hubo cambios dramáticos en la confianza de la vacuna alrededor del mundo que amenazan el éxito de las vacunas aprobadas contra COVID-19 como así también la probabilidad de lograr inmunidad de rebaño. Este seminario web incluirá una discusión en vivo y Preguntas & Respuestas sobre el estado actual de la confianza de la vacuna contra COVID-19 en América Latina, las razones de la vacilación, y propondrá caminos a seguir.

Ver ahora

*Nota: Debido a la rápida evolución del escenario de la pandemia de COVID-19, es posible que parte de la información presentada en este webinar ya no esté actualizada.

*Observação: Devido à rápida evolução do cenário da pandemia de COVID-19, algumas informações apresentadas neste webinar podem não estar mais atualizadas.

Speaker: Prof. Shabir Madhi, University of Witwatersrand, South Africa

Moderator: Prof. Neelika Malavige, ISID Executive Committee Member, Sri Lanka

Abstract: Where are we with delivering safe, efficacious COVID-19 vaccines globally? What are the challenges and opportunities? This webinar provides important updates in the currently approved COVID-19 vaccines and an overview of ongoing Phase 3 trials. Attention will be paid to the vaccination of special groups such as immunocompromised individuals, children and pregnant women. We also discuss the elements required to achieve herd immunity and answer your questions about COVID-19 vaccination!

Watch Here

*This webinar is supported by an Unrestricted Educational Grant from Pfizer Global Medical Grants.

*Please Note: Due to the rapidly evolving COVID-19 environment, some of the information presented in this webinar may no longer be up to date.

Speakers: Dr. Victor Nizet, University of California San Diego

Moderators: Prof. Marc Mendelson & Dr. Connie Walyaro

Abstract: Before the patient has even seen a doctor, their infection is already being treated by multiple antimicrobials - namely the cellular and molecular components of the innate immune system. Conventional screening paradigms in antibiotic discovery are based on MIC/MBC testing in conventional bacteriologic media, and similar tests on patient isolates are used to guide physician management. Antibiotics can synergize with endogenous antimicrobial peptides to effect bacterial killing. These studies will reveal how standard MIC testing can be misleading, overlooking potent antibiotic activities that are recognized only the context of the normal innate immune system.  In this new discovery and treatment framework, drugs used in medicine for other indications (e.g. cholesterol-lowering or antiplatelet drugs), or antibiotics otherwise deemed ineffective, can be "repositioned" for treatment of multi-drug resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) or carbapenemase-resistant strains of Gram-negative pathogens including Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa.

Watch Here

In Collaboration with EcoHealth Alliance, Featuring:
Dr. Peter Daszak, President, EcoHealth Alliance
"Environmental Change and Emerging Infectious Diseases"

Prof. George Gao, Director-General, Chinese Center for Disease Control and Prevention
"One Health and Pandemic Preparedness in China and Beyond"

Dr. Kanta Kumari Rigaud, Lead Enviromental Specialist & Regional Climate Change Coordinayor - Africa Region, World Bank
"Climate Change, Migration, and Infectious Diseases" 

Moderated by: Dr. Larry Madoff (USA) & Dr. Salma Ferchichi (Tunisia)

Watch Here

With generous support from the Bill & Melinda Gates Foundation, ISID presents research selected for presentation at the 19th International Congress on Infectious Diseases (ICID). This collection of ePosters reflects the contributions of early-career investigators working to advance our understanding of infectious disease challenges in low-resource settings. These studies were selected from over 1,900 abstracts due to their quality and the valuable knowledge they add to the field of infectious diseases. With topics ranging from antimicrobial resistance, disease surveillance, HIV situational assessments, metagenomics, arboviruses, and public health epidemiology, there is something to engage all interests. As you interact with these ePosters, please feel free to leave a comment or question for the researchers.

Check Out the ePosters

Speakers: Dr. Marjorie Pollack (USA) & Dr. Uzma Aamir (Pakistan)

Moderators: Dr. Therese Umuhoza (Kenya)

On the night of December 30, 2019, ISID’s Program for Monitoring Emerging Diseases (ProMED) Deputy Editor, Dr. Marjorie Pollack posted a request for information to the ProMED network after being contacted by a trusted colleague about a cluster of undiagnosed pneumonia cases in Wuhan, China. Through her previous experience with SARS decades earlier, Marjorie knew this new threat must be taken seriously. Luckily she sounded the alarm, and in doing so was the first to provide a detailed report alerting the international infectious diseases community to what evolved into what we now know as the global COVID-19 pandemic. With her colleague, Dr. Uzma Aamir, this webinar is an up-close and personal discussion with Marjorie, moderated by Dr. Therese Umuhoza.

Watch Here

Speakers: Prof. Lulu Bravo (The Philippines) & Prof. Francois Venter (South Africa)

Moderators: Prof. Alison Holmes (United Kingdom), Prof. Paul Tambyah (Singapore), Dr. Afreenish Amir (Pakistan)

Abstract: COVID-19 may have complex short- and long-term effects on global infectious disease priorities. With the world’s attention and resources focused towards COVID-19 prevention and response efforts, we are at risk of major infectious diseases making a comeback. As observed during previous crises, the indirect morbidity and mortality effects of the ongoing COVID-19 pandemic may be as important as the direct effects of the pandemic itself. There are widespread disruptions to HIV, TB and malaria service delivery programs globally with shortages in medical supplies, treatments and diagnostics. Existing programs have been hit by lockdowns, changing funding priorities and re-allocation of staff and resources. It is estimated that the disruption of routine childhood immunization services across the globe puts at least 80 million children under one at risk of vaccine-preventable diseases such as measles, mumps, rubella, polio, yellow fever, typhoid, cholera and tetanus. On the other hand, emphasis on infection prevention measures such as hand hygiene and social distancing could reduce the occurrence of community and healthcare associated infectious diseases, providing an opportunity to harness improved practices, behavior changes and attitude modifications relevant to the management of many infections. The full impact of COVID-19 on respiratory diseases and the influenza season remains unknown. Disruptions in disease surveillance and reporting further add to the complexity of understanding the true impact of COVID-19 on communicable diseases.

Watch Here

*Please Note: Due to the rapidly evolving COVID-19 environment, some of the information presented in this webinar may no longer be up to date.

Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.

IKEEP Scientific Committee

Read more about ISID's governance.

Prof. Alison Holmes
Imperial College London, UK

Prof. Alison Holmes
Imperial College London, UK
Conflict of Interest

Paul Tambyah

Prof. Paul Tambyah
National University of Singapore, Singapore
Conflict of Interest

Marc Mendelson

Prof. Marc Mendelson
University of Cape Town, South Africa
Conflict of Interest

Sally Roberts

Prof. Sally Roberts
University of Auckland, School of Medicine, New Zealand
Conflict of Interest

Robert Heyderman

Prof. Robert Heyderman
NIHR Global Health Research Unit on Mucosal Pathogens
London, UK
Conflict of Interest

Gagandeep Kang

Prof. Gagandeep Kang
Translational Health Service and Technology Institute
India
Conflict of Interest

Neelika Malavige

Prof. Gathsaurie Malavige
University of Sri Jayewardenepura
Sri Lanka
Conflict of Interest

Miguel O'Ryan

Prof. Miguel O'Ryan
Faculty of Medicine, University of Chile
Santiago, Chile
Conflict of Interest

Zamberi Sekawi

Prof. Zamberi Sekawi
Universiti Putra Malaysia
Kuala Lumpur, Malaysia
Conflict of Interest

Ursula Theuretzbacher

Prof. Ursula Theuretzbacher
Center of Anti-Infective Agents
Vienna, Austria
Conflict of Interest

Britta Lassmann

Dr. Britta Lassmann
International Society for Infectious Diseases
Boston, USA
Conflict of Interest

For sponsorship opportunities, please reach out to Catherine Crowley.